EC authorises ViiV Healthcare’s Apretude for HIV prevention.
👉 Given as few as six times per year, cabotegravir has demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition in clinical trials.1,2,3,4 👉 With approximately 100,000 people newly diagnosed with…